Icon Plc (NASDAQ:ICLR - Get Free Report) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $159.22 and traded as high as $173.03. Icon shares last traded at $171.76, with a volume of 361,624 shares traded.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on ICLR. Truist Financial upped their target price on Icon from $187.00 to $234.00 and gave the stock a "buy" rating in a research note on Friday, July 25th. Barclays upped their target price on Icon from $155.00 to $180.00 and gave the stock an "equal weight" rating in a research note on Friday, July 25th. Baird R W raised Icon from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 24th. Robert W. Baird raised Icon from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $150.00 to $224.00 in a research note on Thursday, July 24th. Finally, Mizuho upped their target price on Icon from $173.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $218.38.
Read Our Latest Stock Report on ICLR
Icon Stock Performance
The stock has a market cap of $14.37 billion, a PE ratio of 18.31, a price-to-earnings-growth ratio of 2.63 and a beta of 1.17. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.29 and a quick ratio of 1.29. The business has a 50 day moving average price of $162.45 and a two-hundred day moving average price of $158.96.
Icon (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share for the quarter, beating analysts' consensus estimates of $3.18 by $0.08. Icon had a return on equity of 10.95% and a net margin of 9.82%.The firm had revenue of $2.02 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same quarter in the prior year, the firm posted $3.75 earnings per share. The business's quarterly revenue was down 4.8% compared to the same quarter last year. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. As a group, equities research analysts forecast that Icon Plc will post 13.38 EPS for the current fiscal year.
Institutional Trading of Icon
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SVB Wealth LLC purchased a new stake in Icon in the first quarter worth $28,000. Ameritas Advisory Services LLC bought a new stake in shares of Icon during the 2nd quarter valued at $48,000. LRI Investments LLC bought a new stake in shares of Icon during the 2nd quarter valued at $49,000. Blue Trust Inc. boosted its holdings in shares of Icon by 44.0% during the 2nd quarter. Blue Trust Inc. now owns 393 shares of the medical research company's stock valued at $57,000 after buying an additional 120 shares in the last quarter. Finally, NBC Securities Inc. bought a new stake in shares of Icon during the 1st quarter valued at $59,000. Hedge funds and other institutional investors own 95.61% of the company's stock.
Icon Company Profile
(
Get Free Report)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More
Before you consider Icon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Icon wasn't on the list.
While Icon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.